CHEMOMAB THERAPEUTICS LTD. - AMERICAN DEPOSITARY

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

19 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

14 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

30 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

15 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics to Present at October 2024 Investor Conferences

01 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics to Present at September 2024 Investor Conferences

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

21 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

12 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

30 Jul 2024 09:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

26 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics Announces $10 Million Private Placement

25 Jul 2024 07:38:21 By Nasdaq GlobeNewswire

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

25 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

06 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

17 May 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

09 May 2024 07:00:01 By Nasdaq GlobeNewswire

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

08 May 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

02 May 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

24 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

18 Apr 2024 07:00:00 By Nasdaq GlobeNewswire